Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia

Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey

Acute myeloid leukemia (AML) is a heterogeneous disease with a wide variety of clinical presentations, morphological features, and immunophenotypes. The diagnostic approaches to AML that are adopted in Italy have been explored using an online Delphi-based process to expand the global discussion on mandatory tests for the correct diagnosis and, consequently, for optimal management of AML in clinical practice. The final results of the panel of Italian hematologists involved in this work highlight the importance of genetic evaluation for classification and risk stratification and firmly establish that karyotyping, fluorescence in situ hybridization in cases with non-evaluable karyotype, and molecular tests must be performed in every case of AML, regardless of age. Obtaining clinically relevant genetic data at diagnosis is the basis for the success of patient-tailored therapy. The Italian specialists also confirm the role of multidisciplinary diagnostics for AML, now mandatory and expected to become more important in the future context of “precision” medicine.

A deep learning method and device for bone marrow imaging cell detection

BACKGROUND

Morphological analysis of bone marrow cells is considered as the gold standard for the diagnosis of leukemia. However, due to the diverse morphology of bone marrow cells, extensive experience and patience are needed for morphological examination. automatic diagnosis system through the comprehensive application of image analysis and pattern recognition technology is urgently needed to reduce work intensity, error probability and improves work efficiency.

METHODS

In this article, we establish a new morphological diagnosis system for bone marrow cell detection based on the deep learning object detection framework. The model is based on the Faster Region-Convolutional Neural Network (R-CNN), a classical object detection model. The system automatically detects bone marrow cells and determines their types. As specimens have severe long-tail distribution, i.e., the frequency of different types of cells varies dramatically, we proposed a general score ranking loss to solve such a problem. The general score ranking loss considers the ranking relationship between positive and negative samples and optimizes the positive sample with a higher classification probability value.

RESULTS

We verified this system with 70 bone marrow specimens of leukemia patients, which proved that it can realize intelligent recognition with high efficiency. The software is finally integrated into the microscope system to build an augmented reality system.

CONCLUSIONS

Clinical tests show that the response speed of the newly developed diagnostic system is faster than that of trained diagnostic experts.

Safety of FLT3 inhibitors in patients with acute myeloid leukemia

Introduction: Acute myeloblastic leukemia (AML) is the most frequent type of acute leukemia in adults with an incidence of 4.2 cases per 100,000 inhabitants and poor 5-year survival. Patients with mutations in the FMS-like tyrosine kinase 3 (FLT3) gene have poor survival and higher relapse rates compared with wild-type cases.Areas covered: Several FLT3 inhibitors have been proved in FLT3^mut AML patients, with differences in their pharmacokinetics, kinase inhibitory and adverse events profiles. First-generation multi-kinase inhibitors (midostaurin, sorafenib, lestaurtinib) target multiple proteins, whereassecond-generation inhibitors (crenolanib, quizartinib, gilteritinib) are more specific and potent inhibitors of FLT3, so they are associated with less off-target toxic effects. All of these drugs have primary and acquired mechanisms of resistance, and therefore their combinations with other drugs (checkpoint inhibitors, hypomethylating agents, standard chemotherapy) and its application in different clinical settings are under study.Expert opinion: The recent clinical development of various FLT3 inhibitors for the treatment of FLT3^mut AML is an effective therapeutic strategy. However, there are unique toxicities and drug-drug interactions that need to be resolved. It is necessary to understand the mechanisms of toxicity in order to recognize and manage them adequately.